HUTCHMED (00013): TAZVERIK® Included in the First National Commercial Health Insurance Innovative Drug List

Stock News
2025/12/08

HUTCHMED (00013) announced that following the renewal of the national medical insurance agreement with China's National Healthcare Security Administration (NHSA), ELUNATE®, ORPATHYS®, and SULANDA® will continue to be included in the updated National Reimbursement Drug List (NRDL), effective from January 1, 2026. Additionally, TAZVERIK® has been included in the first edition of the National Commercial Health Insurance Innovative Drug List.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10